Stoke Therapeutics stock price target raised to $39 by BTIG on positive data
PositiveFinancial Markets

Stoke Therapeutics has received a boost as BTIG raised its stock price target to $39 following promising data. This positive development highlights the company's potential in the biotech sector, attracting investor interest and signaling confidence in its future growth. Such upgrades can significantly influence market perception and investment strategies, making it an important update for stakeholders.
— Curated by the World Pulse Now AI Editorial System